Last reviewed · How we verify

NCT05250310: SLYM II

The Effect of Structured Lifestyle Modification and Yoga Practice on Metabolic Processes Associated With Cardiovascular Disease

Terminated NA Last updated 11 February 2026
What this trial tests

NA trial testing Chair Yoga in Coronary Artery Disease in 16 participants. Terminated before completion.

Timeline
24 January 2022
Primary endpoint
24 October 2025
24 October 2025

Quick facts

Lead sponsorIcahn School of Medicine at Mount Sinai
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment16
Start date24 January 2022
Primary completion24 October 2025
Estimated completion24 October 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

Adults 18 to 80, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the prospective randomized single center study is to evaluate the effect of a short-term (16 weeks) yoga program on micro RNA (miRNA) expression and cardiovascular disease (CVD) risk factors in patients with CVD.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Connecting the Dots: How MicroRNAs Link Asthma and Atherosclerosis.
    Zimbru RI, Zimbru EL, Bojin FM, Haidar L, et al · · 2025 · cited 2× · PMID 40332077 · DOI 10.3390/ijms26083570

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05250310.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing